All referrals for genomic tests are guided by the National genomics test directory and clinical eligibility criteria.
Please complete all sections on these cards in accordance with our Trust Labelling Policies (NHS internal only).
Request cards that are incomplete can lead to delays in processing, or the wrong test being carried out.
Referral Forms
Haematological Disorders referral card (62kB)
Circulating lung tumour referral card
High risk samples
We are unable to process high risk samples classified as level 3 pathogens or above (eg Tuberculosis (TB), Rabies, Yellow Fever, Vaccinia, Typhoid, Plague, Anthrax, Hanta viruses, Polio type 2).
Any such samples received will be rejected by the laboratory.
Important
It is the responsibility of the requesting Doctor to ensure that specimens and request forms are correctly labelled.
Incorrectly or unlabelled specimens may not be processed by the Laboratory and will be considered as a Risk Incident. Details will be forwarded to the Health and Safety Co-ordinator to identify problem areas.
It is important that known high risk of infection specimens are appropriately labelled. This will allow the laboratory to make a suitable risk assessment, and apply relevant local precautions in respect of trainee and junior staff, pregnant staff, and those who have recently given birth, so as to ensure staff health safety and welfare.
In order to comply with existing Health & Safety Advisory Committee guidelines and legislative requirements, the use of ‘danger of infection’ labels for specimens known or suspected to carry a blood borne virus is strongly recommended.
Turnaround times
UK performance targets are set by the Association for Clinical Genomic Science (ACGS). Laboratories aim to report investigations as soon as possible, and 90% should be within the turnaround targets.
NHSE Reporting Time Targets (17kB)
(samples received from 1st Oct 2018)
The performance varies between investigations and over time, so we urge you to contact us for further detail where turnaround time may impact on clinical care, or in case we can expedite the investigation.
We also urge you to contact us where national turnaround targets shown do not adequately address clinical need, as we may be able to agree a locally set target.